News | April 25, 2025
We’re working at full force to put Bayer back on a profitable growth path: Bill Anderson, CEO, Bayer
Bayer expects 2025 to be the most difficult year of its turnaround
Bayer expects 2025 to be the most difficult year of its turnaround
The company has received final approval from the Department of Pharmaceuticals, Government of India, for foreign investment under applicable regulations
The new facility combines advanced technology, enhanced capacity, and holistic care, reaffirming HCG’s commitment to accessible, world-class oncology in Gujarat
The merged entity ‘Aster DM Quality Care’ will be jointly controlled by Aster Promoters and Blackstone
Women Health Card was launched exclusively for women health workers of the Tiruchirappalli City Corporation
This registration authorizes Nureca Technologies to continue manufacturing and exporting asuite of medical devices to the United States
The company is targeting a Rs. 1,000 crore finished dosages business within the next five years
Strengthening capabilities in Peptide Therapeutics and CDMO services
AstraZeneca Pharma India discontinues manufacturing of Imdur
The amalgamation is expected to create a future-ready, diversified CDMO platform with a technology-led focus across three high-growth verticals-Antibody Drug Conjugates
Subscribe To Our Newsletter & Stay Updated
